Factors associated with complex visual hallucinations during antidepressant treatment

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Complex visual hallucinations (CVH) are a potential adverse effect of antidepressant (AD) treatment.
• Published case reports detail CVH occurrences during various antidepressant therapies, including SSRIs and TCAs.

Purpose of the Study:

• To review and analyze published case reports of complex visual hallucinations (CVH) associated with antidepressant (AD) treatment.
• To investigate the potential mechanisms underlying AD-induced CVH, focusing on neurotransmitter system imbalances.

Main Methods:

• Systematic review of published case reports concerning complex visual hallucinations (CVH) during antidepressant (AD) treatment.
• Analysis of patient data, including concomitant medications and pre-existing neurological conditions.

Main Results:

• Thirteen cases of CVH linked to SSRI treatment, 16 to tricyclic drugs (TCA), and seven to other ADs were identified.
• Concomitant medications and neurological diseases (e.g., dementia) were noted in a subset of patients experiencing CVH.
• TCA-associated hallucinations were often hypnopompic/hypnagogic, potentially linked to sleep architecture disruption.

Conclusions:

• An imbalance favoring cholinergic hypoactivity and serotonergic hyperactivity is implicated in AD-induced CVH.
• Potent anticholinergic effects, like those of amitriptyline, may exacerbate CVH in altered states of consciousness.
• Caution is warranted when prescribing combined serotonergic and anticholinergic ADs, particularly in vulnerable populations like the demented.